ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
2.370
-0.010 (-0.41%)
Jul 14, 2025, 12:35 PM - Market open
ReShape Lifesciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 7.18 | 8.01 | 8.68 | 11.24 | 13.6 | 11.3 | Upgrade
| |
Revenue Growth (YoY) | -13.92% | -7.74% | -22.79% | -17.35% | 20.36% | -25.12% | Upgrade
|
Cost of Revenue | 2.6 | 2.95 | 3.13 | 4.44 | 5.25 | 5.04 | Upgrade
|
Gross Profit | 4.57 | 5.06 | 5.55 | 6.8 | 8.35 | 6.26 | Upgrade
|
Selling, General & Admin | 9.19 | 9.92 | 17.87 | 31.34 | 30.94 | 15.22 | Upgrade
|
Research & Development | 1.68 | 1.8 | 2.32 | 2.54 | 2.37 | 3.5 | Upgrade
|
Operating Expenses | 10.87 | 11.73 | 20.19 | 33.88 | 33.3 | 18.72 | Upgrade
|
Operating Income | -6.3 | -6.67 | -14.64 | -27.08 | -24.96 | -12.46 | Upgrade
|
Interest Expense | -0.04 | - | - | -0.11 | -0.83 | -2.05 | Upgrade
|
Interest & Investment Income | 0.01 | 0.01 | 0.03 | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -0.04 | -0.05 | 0.02 | -0.14 | 0.17 | 0.41 | Upgrade
|
Other Non Operating Income (Expenses) | 2.52 | -0.78 | 4 | 0.01 | -2.81 | - | Upgrade
|
EBT Excluding Unusual Items | -3.85 | -7.48 | -10.59 | -27.32 | -28.43 | -14.1 | Upgrade
|
Merger & Restructuring Charges | - | - | - | - | -2.28 | - | Upgrade
|
Impairment of Goodwill | - | - | - | - | -23.5 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | 0.03 | -0.53 | - | - | Upgrade
|
Asset Writedown | -0.04 | -0.04 | -0.78 | -18.74 | -7.15 | - | Upgrade
|
Other Unusual Items | 0.45 | 0.43 | - | - | -2.06 | -7.72 | Upgrade
|
Pretax Income | -3.43 | -7.09 | -11.34 | -46.59 | -63.42 | -21.81 | Upgrade
|
Income Tax Expense | 0.03 | 0.04 | 0.05 | -0.38 | -0.27 | -0.18 | Upgrade
|
Earnings From Continuing Operations | -3.46 | -7.13 | -11.39 | -46.21 | -63.15 | -21.63 | Upgrade
|
Net Income | -3.46 | -7.13 | -11.39 | -46.21 | -63.15 | -21.63 | Upgrade
|
Net Income to Common | -3.46 | -7.13 | -11.39 | -46.21 | -63.15 | -21.63 | Upgrade
|
Shares Outstanding (Basic) | 0 | 0 | - | - | - | - | Upgrade
|
Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - | Upgrade
|
EPS (Basic) | -96.22 | -345.73 | - | - | - | - | Upgrade
|
EPS (Diluted) | -96.22 | -345.73 | - | - | - | - | Upgrade
|
Free Cash Flow | -4.47 | -4.43 | -17 | -22.03 | -15.73 | -8.94 | Upgrade
|
Free Cash Flow Per Share | -124.31 | -214.66 | - | - | - | - | Upgrade
|
Gross Margin | 63.73% | 63.17% | 63.93% | 60.52% | 61.38% | 55.42% | Upgrade
|
Operating Margin | -87.76% | -83.29% | -168.69% | -240.91% | -183.50% | -110.25% | Upgrade
|
Profit Margin | -48.27% | -89.06% | -131.22% | -411.16% | -464.31% | -191.43% | Upgrade
|
Free Cash Flow Margin | -62.36% | -55.30% | -195.93% | -196.02% | -115.64% | -79.12% | Upgrade
|
EBITDA | -6.28 | -6.65 | -14.49 | -24.93 | -22.99 | -10.79 | Upgrade
|
EBITDA Margin | -87.48% | -83.01% | -166.92% | -221.75% | -169.01% | -95.49% | Upgrade
|
D&A For EBITDA | 0.02 | 0.02 | 0.15 | 2.15 | 1.97 | 1.67 | Upgrade
|
EBIT | -6.3 | -6.67 | -14.64 | -27.08 | -24.96 | -12.46 | Upgrade
|
EBIT Margin | -87.76% | -83.29% | -168.69% | -240.91% | -183.50% | -110.25% | Upgrade
|
Advertising Expenses | - | 0.7 | 2.2 | 6.8 | 3 | 0.5 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.